Regulators Say New Melanoma Drug is ‘Breakthrough’

Wednesday, 24 Apr 2013 04:50 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
U.S. regulators have granted Merck & Co.'s experimental treatment for advanced melanoma a "breakthrough therapy" designation, which could speed development and regulatory review of the product.
 
The medicine, whose chemical name is lambrolizumab, is also being tested against other forms of cancer. It belongs to a promising class of therapies that harness the body's immune system to find and attack cancer cells. It targets a protein called PD-1, or Programmed Death receptor.
 
The FDA created the "breakthrough therapy" designation earlier this year for medicines deemed likely to demonstrate "substantial improvement" over existing drugs.
 
Although it is intended to provide an easier path for drug development, Merck said it was not yet clear what specific benefits the designation would afford.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Exercise Makes Chemo More Effective: Study

Friday, 19 Sep 2014 17:12 PM

Exercise has been shown to boost the effectiveness of chemotherapy in new research that suggests patients who work out m . . .

Berry Extract Shows Promise in Pancreatic Cancer Treatment

Thursday, 18 Sep 2014 15:26 PM

A wild berry extract may boost the effectiveness of a chemotherapy drug used to treat pancreatic cancer, a new study sho . . .

Blood Test Helps Pinpoint Best Prostate Cancer Treatment

Wednesday, 17 Sep 2014 17:18 PM

A blood test that measures DNA from a prostate cancer tumor could provide doctors with a better assessment of the state  . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved